Ravinder Dhawan

Medicine · Health Sciences

18h-index1.6kcitations65works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(33), Cancer Treatment and Pharmacology(17), Prostate Cancer Treatment and Research(13), Protein Degradation and Inhibitors(8), Economic and Financial Impacts of Cancer(8)

Publications65 total

Partnering with rural libraries to increase telehealth utilization in New York state
Journal of the Medical Library Association JMLA·2025Open Access
Real-world treatment patterns and effectiveness among patients with metastatic colorectal cancer treated with ziv-aflibercept in community oncology practices in the USA
Medical Oncology·2017· 31 citedOpen Access
Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting
Medical Oncology·2017· 15 citedOpen Access
Real-world Characteristics and Outcomes of Patients With Metastatic Castration-resistant Prostate Cancer Receiving Chemotherapy Versus Androgen Receptor-targeted Therapy After Failure of First-line Androgen Receptor-targeted Therapy in the Community Setting
Clinical Genitourinary Cancer·2017· 30 cited
Utility of Cancer Value Frameworks for Patients, Payers, and Physicians
JAMA·2016· 58 cited
Treatment Sequences, Patient Characteristics, And Overall Survival Of Patients With Post-Docetaxel Metastatic Castration-Resistant Prostate Cancer In The Community Setting
Value in Health·2016· 1 citedOpen Access
2512 Is there a difference in outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) who receive chemotherapy (CT) vs androgen receptor-targeted therapy (ART) after 1st-line ART in the community setting?
European Journal of Cancer·2015· 2 cited
Clinical features and overall survival (OS) in patients (pts) with post-docetaxel (DTX) metastatic castration-resistant prostate cancer (mCRPC) receiving second-line (2L) therapy in the community setting.
Journal of Clinical Oncology·2015
Sequencing of chemotherapy and androgen-axis inhibitors (AAIs) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Journal of Clinical Oncology·2015
Real-world treatment patterns and outcomes associated with bevacizumab (bev) in metastatic colorectal cancer (mCRC).
Journal of Clinical Oncology·2015
Real-world treatment patterns and effectiveness among patients with metastatic colorectal cancer (mCRC) treated with ziv-aflibercept (Z) in community oncology practices in the United States (US).
Journal of Clinical Oncology·2015
Budgetary impact of adding ziv-aflibercept to a United States health plan formulary as a post-oxaliplatin biologic option for patients with metastatic colorectal cancer (mCRC).
Journal of Clinical Oncology·2015· 1 cited
Utilization patterns of abiraterone acetate before and after chemotherapy in patients with metastatic castration-resistant prostate cancer in the Veterans Health Administration System.
Journal of Clinical Oncology·2014
Characteristics Of Patients Included In The Myelofibrosis Real-World Practice-Based Network Research (ENRiCH) Data Platform
Blood·2013· 3 cited
The Cost-Effectiveness of Initial Treatment of Multiple Myeloma in the U.S. With Bortezomib Plus Melphalan and Prednisone Versus Thalidomide Plus Melphalan and Prednisone or Lenalidomide Plus Melphalan and Prednisone With Continuous Lenalidomide Maintenance Treatment
The Oncologist·2013· 60 citedOpen Access
Health‐related quality of life in elderly, newly diagnosed multiple myeloma patients treated with <scp>VMP</scp> vs. <scp>MP</scp>: results from the <scp>VISTA</scp> trial
European Journal Of Haematology·2012· 70 cited
Healthcare resource use in advanced prostate cancer patients treated with docetaxel
Journal of Medical Economics·2012· 18 cited
Comparison of medical resource use and associated cost before and after docetaxel treatment among prostate cancer patients.
Journal of Clinical Oncology·2011
Effect of abiraterone acetate (AA) on pain control and skeletal-related events (SRE) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) post docetaxel (D): Results from the COU-AA-301 phase III study.
Journal of Clinical Oncology·2011· 31 cited
Prevalence of prostate cancer (PC) clinical states (CS) in the United States: Estimates using a dynamic progression model.
Journal of Clinical Oncology·2011· 8 cited
page 1 of 4Next →

Frequent Co-authors

Helgi van de Velde(10), Mei Sheng Duh(9), Andrew Cakana(6), Francis Vekeman(6), Joris Diels(6), Michel Delforge(6), William Oh(5), Marjolaine Gauthier‐Loiselle(5), Eirini Katodritou(5), Rita Ganguly(5), Hadewijch De Samblanx(5), Dominique Dubois(4), Hui Huang(4), Hongliang Shi(4), Caroline Korves(4), Raymond Miao(4), Wendy Y. Cheng(4), Konstantinos Zervas(4), Javier de la Rubia(4), Samir Bhattacharyya(3)